XTL Biopharmaceuticals Ltd. filed a Form 6-K on November 18, 2026, reporting financial results for the six months ended June 30, 2026, including the completion of its acquisition of 83.4% of Psyga Bio Ltd. and a private placement that raised gross proceeds of $1,500 thousand.
Key Highlights
- Psyga acquisition closed June 30, 2026: XTL acquired 83.4% of Psyga Bio Ltd. for total consideration of $3,534 thousand, comprising $3,361 thousand in fair value of shares and $173 thousand in contingent consideration, with goodwill of $3,184 thousand recognized.
- Private placement raised $1,500 thousand: The June 29, 2026 placement consisted of 555,555 ADSs at $2.70 per ADS, along with Series A, Series B, and contingent Series C warrants, all exercisable for five years.
- Cash position increased to approximately $1.80 million: Cash and cash equivalents rose from approximately $0.08 million as of December 31, 2025, an increase of approximately $1.72 million.
- Net loss from continuing operations was $899 thousand: General and administrative expenses totaled $858 thousand for the period, up from $510 thousand in the corresponding 2025 period.
- Total equity turned positive at $2,632 thousand: The company moved from a capital deficiency of $254 thousand as of December 31, 2025, primarily due to share issuances related to the Psyga acquisition.
- No revenues reported: According to the filing, there were no revenues from continuing operations for the six months ended June 30, 2026 or the corresponding 2025 period.
XTL Biopharmaceuticals Discloses Psyga Deal Terms and Half-Year Financials
According to the filing, XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) completed the acquisition of 83.4% of Psyga Bio Ltd. on June 30, 2026, the final day of the reporting period. The company described Psyga as "an Israeli biotechnology company focused on the research, development and commercialization of proprietary products derived from psychedelic and functional mushrooms." The transaction was accounted for as a business combination under IFRS 3, and because it closed on the last day of the period, Psyga's results of operations are not included in the consolidated statement of comprehensive loss for the half year. The 492,082,705 ordinary shares issued as consideration had not yet been issued as of June 30, 2026, but were issued after the balance sheet date, as the filing notes under subsequent events. The acquisition required shareholder approval as an interested party transaction, given that director and controlling shareholder Alexander Rabinovich was also a Psyga shareholder.
The filing reports that the June 29, 2026 private placement generated gross proceeds of $1,500 thousand through the issuance of 555,555 ADSs at $2.70 per ADS. Series A warrants carry an exercise price of $2.70 per ADS, reducible to $1.70 upon certain trigger events, while Series B warrants carry an exercise price of $5.00 per ADS, reducible to $2.50. An additional round with two non-interested parties added $300 thousand on substantially similar terms, recorded against a subscription receivable as of June 30, 2026, with funds collected in July 2026. The warrant liabilities from these rounds totaled $1,798 thousand as of June 30, 2026, classified as financial liabilities.
General and administrative expenses for the period were $858 thousand, with the $348 thousand increase over the prior year driven mainly by a $128 thousand rise in share-based compensation and a $126 thousand increase in directors' fees, according to the filing. Finance expenses, net were $41 thousand for the six months ended June 30, 2026, compared to finance income, net of $1,919 thousand in the corresponding 2025 period. The filing also notes that The Social Proxy Ltd. was deconsolidated effective January 1, 2025 and is presented as a discontinued operation, with the loss from discontinued operations in the first half of 2025 amounting to $6,210 thousand.
What Was Disclosed
XTL Biopharmaceuticals filed its half-year financial results for the six months ended June 30, 2026, disclosing the completion of the Psyga Bio acquisition, a $1,500 thousand private placement, a shift to positive total equity of $2,632 thousand, and a net loss from continuing operations of $899 thousand with no revenues recorded.


Please wait processing your request...